ReviewJournal of intensive care2026
Remimazolam in pediatric sedation and anesthesia: current perspectives and clinical considerations.
Review in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam is a novel, short-acting benzodiazepine that acts as a high-affinity selective ligand for the GABA-A receptor. Since its approval, growing evidence has demonstrated its safety and efficacy for sedation and anesthesia in adult patients. Recently, increasing interest has emerged regarding the utility of remimazolam in pediatric patients due to its favorable characteristics, including its limited suppressive effect on respiration and circulation in comparison to other sedatives. However, its clinical use in pediatric patients requires special consideration despite the overall safety profile of remimazolam. Because of differences in body composition and dynamic physiological changes during growth and development, the pharmacokinetic and pharmacodynamic properties of remimazolam in children may differ from those in adults. Therefore, a clear understanding of its pharmacological properties, potential indications, limitations, and reverse options is essential for clinical use. Previous studies have suggested that higher doses relative to body size may be required in pediatric patients than in adult patients for adequate sedation and anesthesia. While body weight-based dosing regimens are straightforward, age-related differences in pharmacokinetics and pharmacodynamics may increase the risk of under- or overdosing. The use of concentration prediction models may assist in dose and infusion rate adjustments. Advances in electroencephalogram monitoring during sedation and anesthesia may also provide valuable guidance, although age-dependent EEG differences and the distinct effects of remimazolam in comparison to other sedatives require further investigation. Despite its short-acting nature and low risk of accumulation, the combination of relatively high dose requirements and potentially reduced clearance in children raises a theoretical concern regarding rebound effects in this population. Therefore, careful dose titration, appropriate monitoring, and judicious reversal are necessary to ensure safe administration in pediatric practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.